Synta Pharmaceutical launches its proprietary Small Molecule Hsp90-inhibitor Drug Conjugate platform

|By:, SA News Editor

Synta Pharmaceuticals (SNTA) says it's launching its Hsp90-inhibitor Drug Conjugate platform, with the intention of creating a new class of anti-cancer therapies.

The objective is to create novel drug conjugates that exploit Hsp90 biology to selectively deliver potent anti-cancer payloads to cancer cells.

The drug developer expects to launch its first investigational new drug in next 18 months.